England’s reported 419 community prescriptions of GLP-1 medicines to under-18s should shift the debate away from adult weight-loss fashion and towards the safeguards around paediatric care. The number is important, but it is too limited and incomplete to answer the most important question: whether every child receiving these drugs has the specialist support and long-term follow-up that clinicians say are necessary.
The Guardian reported that 419 prescriptions were issued in the 2025-26 financial year, including 10 for children under 12, based on Freedom of Information data from the NHS Business Services Authority. In the four months from April to July, the newspaper reported 341 prescriptions for children, including 15 for under-12s.
Those are prescription counts, not a count of individual children. They cover medicines prescribed in England and dispensed in community settings anywhere in the UK, while excluding private prescriptions, prisons and hospitals. The data also do not establish whether each prescription was primarily for weight loss. That makes the figures a signal of use, not a full map of paediatric GLP-1 treatment.
That distinction matters because these medicines can have a legitimate role for children with severe obesity and related conditions when other interventions have not worked. The Guardian quoted clinicians who described GLP-1s as an adjunct in specialist services, rather than a treatment for every child carrying extra weight. The strongest case for their use is therefore clinical need, not a generalised response to obesity statistics.
But specialist care cannot be treated as background detail. Professor Martin Whyte told the newspaper that children starting the medicines need support for diet, growth and wellbeing, alongside a long-term plan and monitoring of growth, puberty, nutrition, mental health, eating behaviours and side effects. He also noted that long-term evidence in growing young people remains limited and that weight can return after treatment stops.
England’s prescription data justify scrutiny, but not alarmism. The public case is for clearer reporting on indications, pathways and follow-up, so that a number in a spreadsheet does not substitute for evidence of safe, sustained care.
Sources
- The Guardian · UK · Source date: 2026-11-14
Independent editorial content. WUA is not affiliated with any political party. 2026-11-14